"Dr Olson's and Mr Chun's appointment to our board comes at an exciting time as we prepare to expand our production capabilities to support a growing list of active immunotherapies utilising our Stellar KLH protein. Their combined expertise in pharmaceutical development and commercialisation and capital markets will be a valuable resource to Stellar and its shareholders," said Stellar President and CEO, Frank Oakes.
Dr Olson has been a member of Stellar's scientific advisory board since June 2014 and has extensive scientific, manufacturing and senior management experience in the biotechnology and pharmaceutical industries. He is currently Chief Technology Officer at Anthera Pharmaceuticals, Inc. and is a Principal Biotechnology Consultant for Compass Biotechnology LLC.
"Having had the opportunity to work closely with Stellar's technology developers and management now for more than 2 years, I am looking to helping Stellar continue to position KLH as the go-to molecule for a broad spectrum of indications and markets," said Dr Olson.
Mr Chun is Managing Partner and founder of Eldred Advisors LLC, an advisory firm specialising in the life sciences. Mr Chun brings broad experience as an investment analyst and strategic adviser to the board, including expertise in therapeutics development and commercialisation, corporate development, strategy and finance.
His previous work includes roles at Goldman, Sachs & Co., Tavistock Life Sciences Co., Amgen, Inc., and Westwicke Partners, LLC.
"The immunotherapy landscape continues to evolve at a rapid pace, and I am excited to work with the Stellar team as the company expands upon the distinct role it can play in the space," said Mr Chun.
